what does spin back mean
Indiana encouraged by 'total team effort' with Miami (OH) up nextELIZABETHTON — State and local leaders came together on the grounds of the former Carter County Workforce Development Complex on a cold Thursday afternoon to break ground on a $40 million state project to be called the Carter County Higher Education Center. It will provide new classrooms and other facilities to support the Carter County campuses of Northeast State Community College and the Tennessee College of Applied Technology Elizabethton. It will also provide accommodations for the Middle College program of Carter County School System, the second largest middle college program in the state. The project will add about 71,000 gross square feet of new space. Buildings will include high-bay training spaces, laboratories, and classrooms It will also have space for administrative, student, and support requirements for academic programs and hands-on instruction. “This is a historic occasion,” said Tennessee Board of Regents Chancellor Flora W. Tydings. She praised two people for making the education center possible: Carter County Mayor Patty Woodby and Tennessee Governor Bill Lee. Tydings said Woodby was “the brains behind the building.” Tydings said Woodby's passion and spirit made it happen. She said the other force that made it possible was when Gov. Lee said “I have decided to run the table on your master plan. We are going to put the whole thing in the budget.” She said that amounted to $1 billion. Tydings said that when she goes to other parts of the country and talks about the fact that her governor and the state legislature voted to spend $1 billion into the system, they look at her like she is not telling the truth. She said the next thing they ask is if the state floated a bond for the project. She said the state was not borrowing, it was paying cash because Tennessee is the best managed state in the nation, thanks to the legislators. She said two of the best partners in the state education system, the TCAT and the community college, are coming together to make the project into "a center of higher education learning, where people will come, and they will get a job, and it will change their life and change the lives of their families, and it will change the community. I can’t wait to be back in 2026 to cut the ribbon on this building.” Mayor Woodby said the education center was the first project she took on when she became mayor. She said the irony is that three years ago on this day, Dec. 5, she had Gov. Lee tour this ground to discuss the idea of building an education center on the site. She said her hope is that this facility will enable “our children to enter into the workforce, but not only have jobs but be able to purchase homes and raise their families in this community. To not have to leave to look for work. We want them to be able to stay here and love our community.” Senator Rusty Crowe represented Carter County and told the Johnson City Press “I have to say that Mayor Woodby used Sen. Jon Lundberg and I early on to make this happen. She was laser focused on this approach for our students. We met in my office in Nashville for a call with Chancellor Tydings to try to secure the $40 million appropriation for the project. Mayor Woodby was very convincing. Chancellor Tydings was excited about this approach and she and Gov. Lee made this happen.” Northeast State Community College President Jeff McCord and Tennessee College of Applied Technology President Heath McMillian both pledged to be strong supporting partners in the project. McMillian said “the new center and the partnership with Northeast State will help us better serve students and provide more opportunities to gain the skills needed for local careers.” McCord said “Northeast State is proud to be a partner in the Carter County Higher Education Center and looks forward to the positive impact it will have on the prosperity of the people of Carter County. The good things happening on this site will no doubt ripple across the region.” The facility is scheduled to open in fall 2026, with Thompson & Litton, an architectural, engineering, and land surveying firm based in Wise, Va. overseeing the project’s design. Stay Informed: Subscribe to Our Newsletter TodayA try, a scrap with a star and a trophy from grandma: Sione’s incredible day
Aligos Therapeutics ( NASDAQ:ALGS – Get Free Report ) and Moderna ( NASDAQ:MRNA – Get Free Report ) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, risk, valuation, profitability and institutional ownership. Volatility and Risk Aligos Therapeutics has a beta of 2.11, indicating that its share price is 111% more volatile than the S&P 500. Comparatively, Moderna has a beta of 1.69, indicating that its share price is 69% more volatile than the S&P 500. Analyst Ratings This is a summary of current ratings and recommmendations for Aligos Therapeutics and Moderna, as reported by MarketBeat. Profitability This table compares Aligos Therapeutics and Moderna’s net margins, return on equity and return on assets. Earnings and Valuation This table compares Aligos Therapeutics and Moderna”s gross revenue, earnings per share and valuation. Aligos Therapeutics has higher earnings, but lower revenue than Moderna. Moderna is trading at a lower price-to-earnings ratio than Aligos Therapeutics, indicating that it is currently the more affordable of the two stocks. Insider & Institutional Ownership 60.4% of Aligos Therapeutics shares are held by institutional investors. Comparatively, 75.3% of Moderna shares are held by institutional investors. 8.8% of Aligos Therapeutics shares are held by insiders. Comparatively, 15.7% of Moderna shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Summary Moderna beats Aligos Therapeutics on 9 of the 15 factors compared between the two stocks. About Aligos Therapeutics ( Get Free Report ) Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I clinical trial for the treatment of CHB. In addition, it develops ALG-097558, which is in Phase 2 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH; license agreement with Emory University to provide hepatitis B virus capsid assembly modulator technology; license agreement with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California. About Moderna ( Get Free Report ) Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts. Receive News & Ratings for Aligos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aligos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter .WACO, Texas (AP) — Georgia's Dasha Vidmanova and Columbia's Michael Zheng won NCAA singles tennis titles on Sunday. Vidmanova, a 21-year-old senior from the Czech Republic, beat DJ Bennett of Auburn 6-3, 6-3 for the Bulldogs' first women's singles championship since 2010. Zheng, a 20-year-old junior from Montville, New Jersey, beat Ozan Baris of Michigan State 6-2, 4-6, 6-2 to become the first Ivy League player to collect an NCAA men's singles crown since 1922. The final between Zheng and Baris was the first men's NCAA tennis singles final between two Americans since 2017. More AP tennis: https://apnews.com/hub/tennis
AP Sports SummaryBrief at 4:50 p.m. ESTThrivent Financial for Lutherans Sells 671 Shares of Stifel Financial Corp. (NYSE:SF)Upcoming Smartphones In Early 2025 That Are Worth The Wait
- Previous: what does ph of 9 mean
- Next: what is proton spin
